Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.52 |
| ▸ | CA12 | O43570 | 13/20 | 0.52 |
| ▸ | CA9 | Q16790 | 13/20 | 0.52 |
| ▸ | CA1 | P00915 | 12/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.52 |
| ▸ | CA5A | P35218 | 5/20 | 0.52 |
| ▸ | CA4 | P22748 | 4/20 | 0.52 |
| ▸ | CA6 | P23280 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.52 |
| ▸ | CA3 | P07451 | 3/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6544412 | 0.94 | CA2 (0.52) | CA2CA12CA9CA1CA14 | |
| SCHEMBL5923176 | 0.81 | HTR6 (0.48) | CA2CA12CA9CA1CA14 | |
| SCHEMBL6296397 | 0.79 | CA2 (0.53) | CA2CA12CA9CA1CA14 | |
| SCHEMBL4714329 | 0.78 | CA2 (0.62) | CA2CA12CA9CA1CA14 | |
| SCHEMBL3617107 | 0.77 | ALDH1A1 (0.52) | CA2CA12CA9CA1CA14 | |
| SCHEMBL11740151 | 0.77 | HTR6 (0.33) | CA2CA12CA9CA1CA14 | |
| SCHEMBL6311791 | 0.77 | HTR6 (0.33) | CA2CA12CA9CA1CA14 | |
| SCHEMBL28055 | 0.77 | ENPP2 (0.39) | — | |
| SCHEMBL527816 | 0.77 | TSHR (0.52) | CA2CA12CA9CA1CA14 | |
| SCHEMBL28435387 | 0.77 | MEN1 (0.38) | CA2CA12CA9CA1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 923 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-12 | — | — | US | claimed |
| EP-3923911-B1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | LUTRIS PHARMA LTD (IL) | 2023-07-12 | — | — | EP | claimed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-116234546-A | GPX4 inhibitors, pharmaceutical compositions thereof and their use in the treatment of GPX4 mediated diseases | 嘉兴优博生物技术有限公司 | 2023-06-06 | — | — | CN | claimed |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | claimed |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-01-05 | — | — | US | claimed |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| WO-2000040583-A2 | IMIDAZO[4,5-C]-PYRIDINE-4-ON-DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-07-13 | — | — | WO | claimed |
| WO-1999057101-A1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-11 | — | — | WO | claimed |
| EP-0625550-B1 | Dye mixtures, 1:2 cobalt complex formazan dyes and their use | CIBA GEIGY AG (CH) | 1999-09-01 | — | — | EP | claimed |
| CN-1177343-A | Cell adhesion inhibitors | BIOGEN INC (US) | 1998-03-25 | — | — | CN | claimed |
| US-5459131-A | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1995-10-17 | — | — | US | claimed |
| EP-0625550-A1 | Dye mixtures, 1:2 cobalt complex formazan dyes and their use | CIBA-GEIGY AG (CH) | 1994-11-23 | — | — | EP | claimed |
| EP-0533182-A1 | Triazolium thiolate baths for silver halide development acceleration | EASTMAN KODAK COMPANY (US) | 1993-03-24 | — | — | EP | claimed |
| EP-0061731-B2 | NOVEL PHOSPHORIC ESTER AND A METHOD FOR QUANTITATIVE ANALYSIS OF AN ALKALINE PHOSPHATASE USING THE SAME AS A SUBSTRATE | Fuji Photo Film Co., Ltd. (JP) | 1992-01-29 | — | — | EP | claimed |
| EP-0239874-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their application | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-07 | — | — | EP | claimed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | PLK1, HSP90B1, CEP170 | CA2 1438/4885CA12 2981/4885CA9 4767/4885 |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, RB1, MKI67 | CA2 782/4885CA12 1285/4885CA9 444/4885 |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | CDK5, CDK5R1, PKD1 | CA2 2907/4885CA12 4550/4885CA9 3396/4885 |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CA2 1492/4885CA12 3563/4885CA9 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.